0.3166
price up icon1.25%   0.0039
after-market After Hours: .33 0.0134 +4.23%
loading

Cellectar Biosciences Inc Stock (CLRB) Latest News

pulisher
Mar 11, 2025

Cellectar Biosciences Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView

Mar 11, 2025
pulisher
Mar 11, 2025

Cellectar Biosciences, Inc. to Present at 37th Annual Roth Conference - Nasdaq

Mar 11, 2025
pulisher
Mar 11, 2025

Cellectar Biosciences to Present at the 37th Annual Roth Conference - Enid News & Eagle

Mar 11, 2025
pulisher
Mar 11, 2025

Cancer Treatment Breakthrough? Cellectar Biosciences Reveals Latest Progress at Major Investor Conference - StockTitan

Mar 11, 2025
pulisher
Mar 10, 2025

Before You Invest, Make Sure You Check This Cellectar Biosciences Inc (NASDAQ: CLRB) Analysis - Stocks Register

Mar 10, 2025
pulisher
Mar 10, 2025

Cellectar Biosciences (NASDAQ:CLRB) Now Covered by Analysts at StockNews.com - Defense World

Mar 10, 2025
pulisher
Mar 08, 2025

Cellectar Biosciences (CLRB) Expected to Announce Quarterly Earnings on Thursday - Defense World

Mar 08, 2025
pulisher
Mar 05, 2025

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025 - GlobeNewswire

Mar 05, 2025
pulisher
Mar 05, 2025

Cellectar Biosciences, Inc. to Report 2024 Financial Results and Corporate Update on March 13, 2025 - Nasdaq

Mar 05, 2025
pulisher
Mar 05, 2025

When Will Cellectar Biosciences Reveal Its 2024 Financial Performance? - StockTitan

Mar 05, 2025
pulisher
Mar 02, 2025

StockNews.com Initiates Coverage on Cellectar Biosciences (NASDAQ:CLRB) - Defense World

Mar 02, 2025
pulisher
Feb 14, 2025

Cellectar Biosciences (NASDAQ:CLRB) Coverage Initiated at StockNews.com - Defense World

Feb 14, 2025
pulisher
Feb 10, 2025

CLRB’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

Feb 10, 2025
pulisher
Feb 10, 2025

Prepare Yourself for Liftoff: Cellectar Biosciences Inc (CLRB) - SETE News

Feb 10, 2025
pulisher
Feb 08, 2025

StockNews.com Begins Coverage on Cellectar Biosciences (NASDAQ:CLRB) - Defense World

Feb 08, 2025
pulisher
Feb 07, 2025

SEC Form 424B3 filed by Cellectar Biosciences Inc. - Quantisnow

Feb 07, 2025
pulisher
Feb 06, 2025

A look into Cellectar Biosciences Inc (CLRB)’s deeper side - SETE News

Feb 06, 2025
pulisher
Feb 06, 2025

Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire

Feb 06, 2025
pulisher
Feb 05, 2025

Cellectar Biosciences, Inc. to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 - Nasdaq

Feb 05, 2025
pulisher
Feb 05, 2025

Cellectar Biosciences Showcases Cancer Treatment Pipeline at Major Healthcare Conference - StockTitan

Feb 05, 2025
pulisher
Feb 05, 2025

Examining Cellectar Biosciences Inc (CLRB) stock is warranted - US Post News

Feb 05, 2025
pulisher
Feb 04, 2025

Cellectar faces Nasdaq delisting over share price rule - MSN

Feb 04, 2025
pulisher
Feb 04, 2025

Market Momentum Report: Cellectar Biosciences Inc (CLRB)’s Positive Close at 0.26 - The Dwinnex

Feb 04, 2025
pulisher
Feb 03, 2025

Rosalind Advisors, Inc. Increases Stake in Cellectar Biosciences Inc - GuruFocus.com

Feb 03, 2025
pulisher
Feb 02, 2025

Cellectar faces Nasdaq delisting over share price rule By Investing.com - Investing.com Australia

Feb 02, 2025
pulisher
Jan 29, 2025

Cellectar Biosciences (NASDAQ:CLRB) Now Covered by StockNews.com - Defense World

Jan 29, 2025
pulisher
Jan 21, 2025

Barclays PLC Trims Stake in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World

Jan 21, 2025
pulisher
Jan 19, 2025

Cellectar Biosciences (STU:NV4) Enterprise Value : €-9.79 Mil (As of Jan. 19, 2025) - GuruFocus.com

Jan 19, 2025
pulisher
Jan 17, 2025

Mustang Bio (NASDAQ:MBIO) Stock Quotes, Forecast and News Summary - Benzinga

Jan 17, 2025
pulisher
Jan 16, 2025

Cellectar Biosciences (FRA:NV4) Gross Margin % : 0.00% (As of Sep. 2024) - GuruFocus.com

Jan 16, 2025
pulisher
Jan 14, 2025

Cellectar Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow

Jan 14, 2025
pulisher
Jan 13, 2025

Oppenheimer keeps Perform rating on Cellectar Biosciences stock on recent update - Investing.com Canada

Jan 13, 2025
pulisher
Jan 13, 2025

Cellectar Biosciences (NASDAQ:CLRB) Earns Sell Rating from Analysts at StockNews.com - Defense World

Jan 13, 2025
pulisher
Jan 12, 2025

Cellectar Biosciences to Highlight 2025 Strategic - GlobeNewswire

Jan 12, 2025
pulisher
Jan 12, 2025

Cellectar's Cancer Drug Iopofosine Achieves Remarkable 83.6% Response Rate in Phase 2 Trial - StockTitan

Jan 12, 2025
pulisher
Jan 09, 2025

S&P Midcap 400 (IDX) QuotePress Release - The Globe and Mail

Jan 09, 2025
pulisher
Jan 09, 2025

S&P Smallcap 600 (IQY) QuotePress Release - The Globe and Mail

Jan 09, 2025
pulisher
Jan 06, 2025

Barclays PLC Has $258,000 Holdings in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World

Jan 06, 2025
pulisher
Dec 28, 2024

Cellectar stock plunges 50% post-market on restructuring news - MSN

Dec 28, 2024
pulisher
Dec 26, 2024

Wall Street’s top 5 stocks with the biggest upside in 2025Finbold - Finbold - Finance in Bold

Dec 26, 2024
pulisher
Dec 23, 2024

Is Now The Time To Buy Cellectar Biosciences Inc (NASDAQ: CLRB) Stock? - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

Neuroblastoma Therapeutic Market: Analyzing the Impact of High - openPR

Dec 23, 2024
pulisher
Dec 19, 2024

Oppenheimer Downgrades Cellectar Biosciences (CLRB) - MSN

Dec 19, 2024
pulisher
Dec 16, 2024

Roth Capital Has Optimistic Outlook of CLRB Q1 Earnings - Defense World

Dec 16, 2024
pulisher
Dec 13, 2024

Cellectar Biosciences Implements Workforce Reduction Plan to Enhance Operational Efficiency - Defense World

Dec 13, 2024
pulisher
Dec 12, 2024

Cellectar Biosciences (FRA:NV4) 10-Year Sharpe Ratio : -0.19 (As of Dec. 12, 2024) - GuruFocus.com

Dec 12, 2024
$35.01
price up icon 3.70%
$307.09
price up icon 0.88%
$32.85
price up icon 1.20%
$19.91
price up icon 7.62%
$100.31
price up icon 1.95%
biotechnology ONC
$249.84
price up icon 1.68%
Cap:     |  Volume (24h):